Oncology - Lambda Biologics

Faster Clinically Relevant Insights

with PDO-Based Evaluation Platform

By integrating immune cells from the tumor microenvironment, we enable more accurate assessment of oncology drugs and immunotherapies – bringing your research closer to predictive, patient-relevant outcomes.

Next-Generation Anti-Cancer Drug Development & Efficacy Evaluation

with Patient-Derived Organoids (PDOs)

High-Fidelity Preclinical Models

Cultured directly from tumor biopsies, our PDOs ensure the ideal preservation the tumor’s genetic fidelity and phenotypic traits. Bypassing the limitations of 2D cell lines or animal models, Lambda’s PDOs provide highly clinically relevant platforms, enabling more accurate prediction of drug efficacy and patient response.

Extensive Organoid Biobanking

Our expansive biobank spans multiple cancer types, offering a diverse library of organoids that supports robust drug screening and discovery. This resource accelerates decision-making across the R&D pipeline and helps identify promising candidates for a variety of tumor profiles.

Fully customized research services

Our platform offers a fully customizable suite of organoid-based preclinical research services designed to meet your unique needs. This includes integrating donor-matched immune microenvironments, personalized PDOs lineups, and generating high-resolution functional data (HCS, scRNAseq, multi-plex IHC, and more).